Clinical trial
A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients
NCT00563355 is registered in ClinicalTrials.gov with Hospital Authority, Hong Kong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients
- Lead sponsor
- Hospital Authority, Hong Kong
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- February 28, 2001
- Completion date
- November 30, 2003
- Enrollment
- 66 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.